Study #2023-0413
Phase II study of Pirtobrutinib, rituximab (PR) in previously untreated low and intermediate risk MCL (mantle cell lymphoma) patients
MD Anderson Study Status
Enrolling
Treatment Agent
Rituximab, Pirtobrutinib
Description
To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mantle Cell Lymphoma
Study phase:
Phase II
Physician name:
Preetesh Jain
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-866-478-2259
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.